Labiotech.eu

Screenshot 2016 10 26 at 1.52.35 PM 1 e1477644606273

News and Trends 28 Oct 2016

Meet Spain’s Gold BIOMEDAList in Celiac Disease

This week we’re heading South back to my hometown, Sevilla! Even well into October, the skies are clear and the sun is shining while we drop by Biomedal, this week’s Biotech. City: Sevilla, Spain Founded: 2000 Employees: 31 Financial data: €2.5M in sales with an impressive 60% growth in the last year Mission: The company has three […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Oct 2016

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […]

October 28, 2016 - 2 minutesmins - By Dani Bancroft

Inside Labiotech 28 Oct 2016

Santé, Labiotech.eu is now 2 years old! (and what a journey so far)

Yes, it’s been already 2 years since Joachim and I moved to Berlin to work full-time on changing the media landscape of Biotech. And this second year has just been exceptional: we are now the leading digital media in Europe with 50k monthly visitors, a team of almost 10 people, solid investors, and over 50 customers. […]

October 28, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 27 Oct 2016

€36M Fundraising to Sequence the Genome of Ireland

Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of the Irish and use the info for the development of new drugs and diagnostics. Genomics Medicine Ireland (GMI) is committed to revolutionizing health care with whole-genome sequencing. The company just raised €36M ($40M) in Series A that will be used to […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

Boehringer enters the Biosimilar War against Blockbuster Humira

Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle

After a promising kick off, Novartis is raising doubts about the future of its CAR-T program with its decision to dissolve and reintegrate the cell and gene therapy division into its immuno-oncology effort. Yes, you read that correctly: despite exciting progress by Novartis’s CAR-T therapy program, the company is reportedly disbanding the cell and gene therapy […]

October 27, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 27 Oct 2016

Oxitec scales up Mosquito production with a new Factory in Brazil

Since Brazil became the first country in the world to deploy GM mosquitos, Oxitec has opened a factory there to produce its Friendly Aedes aegypti. Oxitec has opened a large-scale mosquito factory in Piracicaba, Brazil, to scale up production of their Friendly Aedes aegypti mosquitos. These mosquitos are effectively sterilized so they don’t transmit infectious […]

October 27, 2016 - 2 minutesmins - By Evelyn Warner

guitar singing music song Rawpixel.com fi

News and Trends 26 Oct 2016

Proteins can now Sing about their Anomalies to help cure Diseases

Researchers are generating melodies from proteins’ structures. It could be used to understand protein folding and anomalies that contribute to disease. Protein folding is an infamously difficult phenomenon to understand and predict from sequence data. A collaboration between a resident composer at the University of Tempere in Finland and a scientist at the Francis Crick […]

October 26, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

cells pipetting well plate cells Andrii Slonchak fi

News and Trends 26 Oct 2016

Biosimilars are all the rage, but how do they compare to Generics?

Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold in the next 5 years. But how do they differ from generic drugs? During the past decade, Europe saw the emergence of a new type of drug: biosimilars. The concept of a “similar biological medicinal product” was adopted in EU […]

October 26, 2016 - 5 minutesmins - By External Contributor

News and Trends 25 Oct 2016

The First Peanut Allergy Therapy might soon hit the Shelves

DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 25 at 3.57.12 PM e1477403929643

News and Trends 25 Oct 2016

This Diagnostic Tool beats the Standard for Respiratory Infection Tests

Curetis is drastically reducing the time required to test for severe infectious diseases. The newest incorporation is expected early next year and could soon substitute the hospital standards. Curetis is a German biotech that commercializes diagnostic technologies for infectious diseases. After a very successful IPO last year, the company is advancing its Unyvero platform for fast diagnostics. The […]

October 25, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Meet Spain’s Gold BIOMEDAList in Celiac Disease

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

Santé, Labiotech.eu is now 2 years old! (and what a journey so far)

€36M Fundraising to Sequence the Genome of Ireland

Boehringer enters the Biosimilar War against Blockbuster Humira

UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle

Oxitec scales up Mosquito production with a new Factory in Brazil

Proteins can now Sing about their Anomalies to help cure Diseases

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Biosimilars are all the rage, but how do they compare to Generics?

The First Peanut Allergy Therapy might soon hit the Shelves

This Diagnostic Tool beats the Standard for Respiratory Infection Tests

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!